Human immunodeficiency virus and liver disease: Conference proceedings

✍ Scribed by Kenneth E. Sherman; Vincent Soriano; Raymond T. Chung

• Book ID: 102241261
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 207 KB
• Volume: 51
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.23394

✦ Synopsis

iver disease has emerged as one of the major causes of morbidity and mortality among patients infected with the human immunodeficiency virus (HIV), particularly in regions where highly active antiretroviral therapy (HAART) is widely available. This dramatic change in disease epidemiology is attributable to a complex interaction between etiologic factors that appear to increase the rate of hepatic fibrosis and accelerate progression to end-stage liver disease (ESLD). Key factors include HAART-related hepatoxicity, frequent coinfection with hepatitis B and C virus, and possibly the direct interaction of HIV virus or soluble protein viral products that interact with hepatocytes and other liver resident cell types. Additionally, there is some evidence that gut permeability is altered during active HIV replication, which affects the complex mix of toxins and growth factors present in the portal circulation. It is critical that hepatologists maintain a strong knowledge base to provide the best possible guidance to HIV-infected patients and their healthcare providers.